Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial

ConclusionsRisk assessment using currently available SNPs is justified. Multiple GRS values from evolving sets of SNPs provide a valuable tool for better refining risk.

Source: The Prostate - July 1, 2017 Category: Urology & Nephrology Authors: Haitao Chen, Rong Na, Vignesh T. Packiam, Carly A. Conran, Deke Jiang, Sha Tao, Hongjie Yu, Xiaoling Lin, Wei Meng, S. Lilly Zheng, Charles B. Brendler, Brian T. Helfand, Jianfeng Xu Tags: ORIGINAL ARTICLE Source Type: research